Patient Care
To make an appointment 800-762-6161 or Transfer Center 804-628-9337
Educational ProgramsResearchProgram for Global Surgery at VCUPatient Care at VCU HealthSurgery DivisionsSurgery DirectoryAbout the Department of Surgery at VCU

Gastro-Esophageal Reflux Disease (GERD):
Lap Anti-reflux Surgery (LAR)

LINX® Reflux Management

Endoscopic Stretta Therapy®


VCU Health


Treatment for GERD

LINX® Reflux Management

The LINX® system is for patients with GERD and without large hiatal hernias or severe mucosal damage. It consists of a small ring of interlinked titanium beads with magnetic cores that surgeons implant laparoscopically.

LINX system image of small ring of interlinked titanium beads with magnetic cores.

How the LINX® System works:

illustration of GERD

GERD Figure 1:

A competent lower esophageal sphincter (LES) prevents reflux of gastric contents into the esophagus.

GERD illustration

GERD Figure 2:

If the lower esophageal sphincter (LES) weakens reflux can occur more frequently.

LINX illustration

LINX® Figure 1:

The LINX device augments the function of the lower esophageal sphincter (LES) and reduces reflux.

How LINX system works GERD

LINX® Figure 2:

The LINX device allows the lower esophageal sphincter (LES) to open and th efood bolus to pass.

After implantation, the beads bolster the existing structure of the lower esophageal sphincter (LES) and prevent reflux (VIDEO LINX® Animation). During swallowing, the beads relax, so food passes through the esophagus to the stomach and also allow patients to belch or vomit if necessary. This is an FDA cleared procedure.

Follow this link to watch a Video of a LINX device being implanted.

In a recent study with 5-Year results the LINX Procedure showed to be a Beneficial Treatment for Gastroesophageal Reflux Disease: (Clin Gastroenterol Hepatol. 2015 Jun 2. pii: S1542-3565(15)00763-6. doi: 10.1016/j.cgh.2015.05.028. [Epub ahead of print]

Long-Term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux.

Ganz RA1, Edmundowicz SA2, Taiganides PA3, Lipham JC4, Smith CD5, DeVault KR6, Horgan S7, Jacobsen G7, Luketich JD8, Smith CC9, Schlack-Haerer SC10, Kothari SN11, Dunst CM12, Watson TJ13, Peters J14, Oelschlager BK15, Perry KA16, Melvin S16, Bemelman WA17, Smout AJ18, Dunn D19.

  • 85 percent of patients remained free from dependence on daily GERD medication.
  • Bothersome regurgitation, a debilitating symptom of GERD, was eliminated in 99 percent of patients.
  • Bothersome heartburn was significantly reduced  from 89% at baseline to 11.9% at five years.
  • Patients reported a significant improvement in their  quality of life.

For additional information you can access the LINX Manufacturer Website at



  Web Services Help Desk   

  Virginia Commonwealth University
  School of Medicine
  Department of Surgery  |
  last updated: 10/20/2017